Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

burn rate for the full year of 2009 to remain largely consistent with full-year 2008 net cash burn.

"Important progress was made in 2008 to advance product assets into later stages of development and to expand our portfolio," said Howard H. Pien, Chairman and CEO of Medarex. "These research and clinical development accomplishments, along with our strategy execution and financial discipline, leave Medarex well-positioned for the future. Our focus and efforts in 2009 will progress our business plans and pipeline opportunities towards commercial success. We are also pleased with the regulatory progress being made by our licensing partners, including the Canadian and European approvals of Centocor's STELARA(TM) psoriasis antibody, the first approved antibody generated from our UltiMAb(R) technology available for commercial sale. We also eagerly anticipate the regulatory outcomes for Centocor's golimumab and Novartis' canakinumab antibody programs, which were also generated from our technology in exchange for milestone and royalty payments."

Company and Pipeline Highlights in 2008

  • Announcing the receipt of a milestone payment from our licensing partner, Centocor, Inc., in connection with the December 2008 approval of STELARA(TM) (ustekinumab) for the treatment of chronic moderate to severe plaque psoriasis in Canada. STELARA represents to the first human antibody generated using Medarex's UltiMAb(R) technology to receive market approval. Subsequent developments include the approval and launch of STELARA in Europe and the product's pending regulatory outcome in the U.S.
  • Announcing the receipt of a milestone payment from our licensing partner, Centocor, Inc., in connection with the March 2008 regulatory filing for market approval in Europe for golimumab (CNTO 148), a human anti-TNF-alpha antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    '/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Imagine a day without access to clean, drinkable water ... was no one to help. For more than 783 million ... more than 2.5 billion people will also lack access to ... initiative led by Nevada’s Desert Research Institute (DRI) ... women – who often bear the brunt of the impact ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The COR ... Topical BioMedics, Inc., Rhinebeck, NY, to offer customers a ... topical biomedicine formulas that safely and effectively address muscle, ... new division of Vets Access LLC, Montrose, MI, that ... healing products. , Topical BioMedics is a research and ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 The ... reopening of their newly renovated office in Lawrenceville, NJ. ... Reproductive Science Center of New Jersey’s physicians, and NJ ... and patient care in the areas of infertility and ... for having excellent success rates and providing current, high ...
(Date:2/26/2015)... Beckman Coulter is sponsoring a ... their cargo in cell-to-cell communication,” which will focus on ... cell-to-cell communication. The webinar is free to attend and ... PT. , Every cell in the body can release ... called “exosomes” or “microvesicles.” These vesicles carry a wide ...
(Date:2/26/2015)... February 26, 2015 Body Well Therapy, a ... years of delivering high quality mobile massage services ... other regions across the United States. The company has experienced ... pivotal year as it sets its sights on additional major ... chair massage services. , “We’ve come a long way since ...
Breaking Medicine News(10 mins):Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3
... ... as a director of accounting. , ... Tucson, Ariz. (Vocus) June 16, 2010 -- Ray Brogan, former controller ... Brogan has more than 30 years of experience in financial reporting, budget analysis and ...
... tamoxifen for early-stage breast cancer who developed blood clots were ... women taking tamoxifen who did not develop blood clots, according ... Journal of the National Cancer Institute. Tamoxifen ... and post menopausal patients with hormone receptor-positive breast cancer. One ...
... of Gothenburg, Sweden, explores how an online learning community ... that clear rules facilitate continued web interaction. , ... how a large group of general practitioners interact via ... serves as an online community for exchange of knowledge ...
... American Society for Radiation Oncology (ASTRO) commends the Medicare ... self-referral in cancer care in its report released yesterday. ... to end abuses of the physician self-referral law in ... , "We are very pleased that ...
... immune system to attack healthy cells, study finds , ... finds that rare gene variations are more common in ... the body. These autoimmune disorders include rheumatoid arthritis and ... could lead to better treatments -- although that,s not ...
... remains lethal in a majority of cases, due to late ... LaBaer of the Biodesign Institute at Arizona State University, along ... Hutchinson Cancer Research Center in Seattle, used a novel ... cancer before symptoms appear. The work, which appeared ...
Cached Medicine News:Health News:New Director of Accounting Adds to Talent at Splendido Retirement Community 2Health News:Gene mutation increases thromboembolism risk in women taking tamoxifen 2Health News:Clear rules facilitate continued Web interaction among general practitioners 2Health News:ASTRO applauds MedPAC review of Stark law exception 2Health News:Gene Mutations Offer Clues to Autoimmune Disorders 2Health News:Blood relations 2Health News:Blood relations 3
(Date:2/26/2015)... -- Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or ... a noninvasive  device that tracks blood glucose levels, announced today ... its new scientific advisory board that is expected to ... research, monitoring and treatment. Prof. Dr. ... and Head, Business Development of Profil Institute for Metabolic ...
(Date:2/26/2015)... , Feb. 26, 2015 People ... have the opportunity to participate in research that ... the first independent U.S. psoriasis registry begins recruiting ... joint collaboration with the National Psoriasis Foundation and ... reporting for secukinumab, a new biologic medication by ...
(Date:2/26/2015)... , Feb. 26, 2015 Surna Inc. ... specializing in commercial indoor cannabis cultivation technology, announced ... from start-up to fast-paced manufacturing and engineering company. ... , current Director and CEO, will be stepping ... proud of what the team has accomplished thus ...
Breaking Medicine Technology:Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3Surna, Inc. Announces Senior Leadership Changes 2Surna, Inc. Announces Senior Leadership Changes 3Surna, Inc. Announces Senior Leadership Changes 4
... 1, 2011 PTC Therapeutics, Inc. (PTC) today announced ... of ataluren, an investigational new drug, in adults with ... Respiratory Journal . The published three-month data showed that ... chloride channel activity, CF-related cough and positive trends in ...
... READING, England and BEDMINSTER, N.J., June 30, 2011 ... Inc., today announced that the U.S. Food and Drug ... the management of breakthrough pain in cancer patients 18 ... and who are tolerant to opioid therapy for their ...
Cached Medicine Technology:Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 2Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 3Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 4Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 5Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 2FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 3FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 4FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 5FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 7FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 8
... Shoulder Holder is used for positioning the ... position. The shoulder holder is adjustable with ... arm positions and sizes. The MITT allows ... arm in the shoulder holder during surgery. ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Made exclusively from LactoSorb® Resorbable Copolymer....
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
Medicine Products: